311C90: Increasing the options for therapy with effective acute antimigraine 5HT(1B/1D) receptor agonists

Neurology

Volumn 48, Issue 3 SUPPL. 3, 1997, Pages

  Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN 1B AGONIST; ZOLMITRIPTAN;

ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030937755     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.3_suppl_3.21s     Document Type: Article

References (15)

1. 1 receptors in migraine pathophysiology and treatment. Eur Neurol 1995;2:5-21.
2. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in acute treatment of migraine and cluster headache. Drugs 1994;47:622-651.
3. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose defining study. Eur Neurol 1991; 31:300-305.
4. Visser WH, de Vriend RHM, Jaspers NMWH, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996;47:46-51.
5. 1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996;36(suppl 2):13-18.
6. McNaughton FL. The innovation of the intracranial blood vessels and the dural sinuses. In: Cobb S, Frantz AM, Penfield W, Riley HA, eds. The circulation of the brain and spinal cord. New York: Hafner Publishing, 1966:178-200.
7. Moskowitz MA, Reinhard JF, Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the 5th cranial nerve: is there a relation to the headache phase of migraine? Lancet 1979;2:883-885.
8. Goadsby PJ, Hoskin KL. Trigeminal neuronal activity is inhibited by intravenous administration of 311C90 in the cat. Cephalalgia 1995;15(suppl 14):106.
9. Schoenen J, Proietti A, Afra J, Peck RW. Further characterization of pre-clinical 311C90 profile in man: CNS effects assessed with neurophysiological methods. Proc 3rd European Headache Conference 1996;14-15.
10. Zeneca, data on file.
11. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-294.
12. Seaber E, Dixon E, Veronese R, et al. The novel antimigraine drug 311C has no clinically significant interactions with likely concomitant medications. Eur Neurol 1996;3(suppl 5):P407.
13. Zagami AS, for the 311C90 Long-Term Study Group. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 1997;48(suppl 3):S25-S28.
14. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks: a review of controlled clinical trials. Cephalalgia 1993;13:238-244.
15. Diener HC, Klein KB. The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine. Proc 3rd European Headache Conference 1996;10-11.